Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC lung cancer cooperative group

European Journal of Cancer

Volumn 33, Issue 13, 1997, Pages 2211-2215

  Sahmoud, T ^a   Postmus, P E ^b   Van Pottelsberghe, Ch ^a   Mattson, K ^c   Tammilehto, L ^d   Splinter, T A W ^e   Planting, A S T ^e   Sutedja, T ^b   Van Pawel, J ^f   Van Zandwijk, N ^g   Baas, P ^g   Roozendaal, K J ^h   Schrijver, M ⁱ   Kirkpatrick, A ^a   Van Glabbeke, M ^a   Ardizzoni, A ^j   Giaccone, G ^k  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f Krankenhaus Gauting   (Germany)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h OLV Gasthuis   (Netherlands)

ⁱ Location Alkmaar   (Netherlands)

^j UNIVERSITY OF GENOA   (Italy)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Etoposide; Mesothelioma; Phase II

Indexed keywords

ETOPOSIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL RATE;

EID: 0031408594     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00183-4     Document Type: Article

References (28)

1. De Klerk NH, Armstrong BK. The epidemiology of asbestos and mesothelioma. In Henderson DW, Shelkin KB, Langlois SLP, Whitaker D, eds. Malignant mesothelioma. New York, Hemisphere, 1992, 223-243.
2. Chailleux E, Pioche D, Chopra S, et al. Epidemiologie du mesotheliome pleural malin dans la region de Nantes-Saint Naziare. Evolution 1956-1992. Rev Mal Respir 1995, 12, 353-357.
3. Mowe G, Andersen A, Osvoll P. Trends in mesothelioma incidence in Norway 1960-1988. Toxicol Ind Health 1991, 7, 47-52.
4. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987, 78, 1053-1560.
5. Enterline PE, Henderson VL. Geographic patterns for female pleural mesothelioma deaths for 50 states. J Natl Cancer Inst 1987, 79, 31-37.
6. Walker AM, Loughlin JE, Freidlander ER, et al. Projections of asbestos-related disease 1980-2009. J Occup Med 1983, 25, 409-425.
7. Ong ST, Vogelzang NJ. Chemotherapy in malignant mesothelioma: A review. J Clin Oncol 1996, 14, 1007-1017.
8. Chen GL, Yang L, Rowe TC, et al. Non-intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984, 259, 9182.
9. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al. Etoposide (VP16-213). Current status of an active anticancer drug. N Engt J Med 1985, 312, 692-700.
10. Clark PI, Slevin ML. The clinical pharmacology of etoposide and tenoposide. Clin Pharmacokinet 1987, 12, 223-252.
11. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989, 7, 1333-1340.
12. Clark PI, Slevin ML, Joel SP, et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence on efficacy and toxicity. J Clin Oncol 1994, 12, 1427-1435.
13. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol (Suppl 2) 1990, 17, 32-35.
14. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol (Suppl 2) 1990, 17, 36-39.
15. Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990, 26, 818-821.
16. Nissen NI, Larson V, Petersen H, Thompson K. Cancer chemotherapy. Chemother Rep 1972, 56, 769-777.
17. Falkson G, Van Dijk JJ, Van Eden EB, Van Merwe AM, Van den Berg JA, Falkson H. A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP16-213. Cancer 1975, 35, 1141-1144.
18. Nissen NI, Dombernowsky P, Hansen H, Larson V. Phase I clinical trial of an oral solution of VP-16-213. Cancer Treat Rep 1976, 60, 943-945.
19. Van Gelder T, Hoogsteden HC, Vandenbroucke JP, Van der Kwast TH, Planteydt HT. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma. Virchows Arch A Pathol Anat 1991, 418, 315-317.
20. Butchart EG, Aschcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesodielioma of the pleura. Experience with 9 patients. Thorax 1976, 31, 15-24.
21. Mattson K. Natural history and clinical staging of malignant mesothelioma. Eur J Resp Dis 1982, 63, 87.
22. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva, WHO Offset Publication number 48, 1979.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
24. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new therapeutic agent. J Chron Dis 1961, 13, 346-353.
25. Harvey VJ, Slevin ML, Joel SP, et al. Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 1985, 21, 1315-1319.
26. Schabel FM, Trader MW, Laster WR, et al. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross resistance studies with tumors in mice. Cancer Treat Rep 1979, 63, 1459-1473.
27. Eisenhauer EA, Evans WK, Murray N, et al. A phase II trial of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. Investigational New Drugs 1988, 6, 329.
28. Planting AST, van der Burg MEL, Goey SH, et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995, 6, 613-615.